Optinose Announces XHANCE Co-Promotion Agreement with Kaléo - Seite 2
DRUG INTERACTIONS: Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.
USE IN SPECIFIC POPULATIONS: Hepatic impairment. Monitor patients for signs of increased drug exposure.
INDICATION AND USAGE: XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.
Lesen Sie auch
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby
identified as forward-looking statements for this purpose and include, among others, the expected commencement of promotional activities by kaleo in the fourth quarter of 2020; the potential
benefits of the agreement, including without limitation, increased reach and frequency and the potential to grow appreciation for XHANCE in the target audience; as well as other statements
regarding the Company's future operations, prospects, objectives and other future events. Forward-looking statements are based upon management’s current expectations and assumptions and are subject
to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements
including, among others: the COVID-19 environment restricting prescriber interactions and patient flow; the effectiveness of kaleo’s sales representatives in promoting XHANCE; physician and patient
acceptance of XHANCE in the segment of prescribers to be called on by kaleo; and the risks, uncertainties and other factors discussed under the caption "Item 1A. Risk Factors" and elsewhere in the
Company’s most recent Form 10-K and Form 10-Q filings with the Securities and Exchange Commission - which are available at www.sec.gov. As a result, you are cautioned not to place undue reliance on
any forward-looking statements. Any forward-looking statements made in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update such
forward-looking statements, whether as a result of new information, future developments or otherwise.